Cornell Belcher, Brilliant Corners Research's founder and president, and Brian Gardner, Stifel's chief Washington policy ...

Stifel lowered the firm’s price target on Crispr Therapeutics (CRSP) to $53 from $59 and keeps a Hold rating on the shares following the ...

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug ...

will present a corporate overview at the Stifel Healthcare Conference, on November 18, 2024 at 1:50 p.m. ET in New York, NY.

Stifel Nicolaus analyst Tore Svanberg maintained a Sell rating on Alpha and Omega (AOSL – Research Report) today and set a price target ...

Eric Lyon, a former senior managing director, B. Riley Wealth Management, jumped to Kestra Investment Services at the start ...

Investment bank B. Riley Financial said on Friday it had agreed to sell a portion its traditional wealth management business ...

B. Riley Financial Inc. agreed to sell a portion of its wealth-management business to Stifel Financial Corp. for as much as ...

Stifel Financial received final federal approval for its Stifel North Atlantic AM-Forward Fund, which is designed to provide ...

Take Raymond James Financial Inc. and Stifel Financial Corp., both of which reported quarterly earnings this week. Stifel ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the Stifel 2024 Healthcare Conference on Tuesday, ...